According to Zhitong Finance App News, Rongchang Biotech (688331.SH) announced that the company expects to achieve net profit attributable to owners of the parent company for the first half year of 2026 of about 4.7 billion yuan. Compared with the same period last year, it will turn a loss into a profit.

During the reporting period, domestic sales revenue of the company's core products, tetracip and verticitumab, continued to grow; at the same time, the company signed an exclusive licensing agreement with AbbVie Group Holdings (“AbbVie”) for RC148. AbbVie will obtain exclusive rights to develop, produce and commercialize RC148 outside of Greater China. Technical licensing revenue has increased dramatically, and is expected to be profitable in the first half of 2026.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.